@article{3030660,
    title = "Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of
clinical trials",
    author = "Panagiotou, E. and Gomatou, G. and Trontzas, I. P. and Syrigos, N. and and Kotteas, E.",
    journal = "Clinical and Translational Oncology",
    year = "2022",
    volume = "24",
    number = "2",
    pages = "161-192",
    publisher = "SPRINGER INT PUBL AG",
    issn = "1699-048X, 1699-3055",
    doi = "10.1007/s12094-021-02688-5",
    keywords = "Cyclin-dependent kinases; Antineoplastic agents; Clinical trials;
Protein kinase inhibitors; Cell cycle checkpoints",
    abstract = "Cyclin-dependent kinases (CDKs) play a key regulating role in the cell
cycle, which is almost universally altered in cancer, leading to
sustained proliferation. Early pan-CDK inhibitors showed poor results in
clinical trials for solid malignancies, as the lack of selectivity
produced significant toxicity. The production of more selective
inhibitors led to significant developments in cancer therapy, as CDK4/6
inhibitors in combination with endocrine therapy changed the landscape
of the treatment of hormone-receptor positive (HR +) metastatic breast
cancer. Recently, Trilaciclib demonstrated benefits regarding
hematological toxicity compared to placebo when administered in
combination with chemotherapy in small cell lung cancer. Newer agents,
such as SY-5609, a selective CDK7 inhibitor, have also shown promising
results in early clinical trials. In this paper, we review the data from
clinical trials of CDK inhibitors in solid tumors, either as a
monotherapy or in combination with other agents, with an emphasis on
novel agents and potential new indications for this drug class."
}